Clinical trials: Controlled Diabetes
Cardiovascular Risk Factor, Cardiovascular Diseases
Umbrella Review of the DASH Dietary Pattern and Cardiometabolic Risk
The European Association for the Study of Diabetes (EASD) guidelines have not made any specific recommendations regarding the Dietary Approaches to Stop Hypertension (DASH) diet, a dietary pattern that emphasizes fruits and…
- Conditions
- Cardiovascular Risk Factor, Cardiovascular Diseases, Coronary Heart Disease, Stroke
- Trial name
- NCT03542370
- Testing
- DASH dietary pattern
- Where
- Canada
- Volunteers
- 1 people
- Sponsor
- University of Toronto
Diabetes Mellitus Type 2
A Titration Study of a Glucagon-Like Peptide-1 (GLP-1) Analogue in Patients With Type 2 Diabetes Treated With Metformin.
This 4 arm study will evaluate the tolerability, efficacy and pharmacodynamics of different doses of a GLP-1 analogue in patients with type 2 diabetes who are treated with a stable dose of metformin.
- Trial name
- NCT00460941
- Testing
- Taspoglutide 20mg, Taspoglutide 20mg-30mg, Taspoglutide 20mg-40mg
- Where
- 29 sites in United States, Australia and 5 more
- Volunteers
- 133 people
- Sponsor
- Hoffmann-La Roche
Diabetes Type 2, Impaired Glucose Tolerance
ARA290 in T2D (Effects of ARA 290, an Erythropoietin Analogue) in Prediabetes and Type 2 Diabetes)
The purpose of this study is to determine whether a non-hematopoietic erythropoietin analogue, ARA 290, exerts beneficial effects on blood glucose levels and insulin secretion in persons with prediabetes (impaired glucose…
- Conditions
- Diabetes Type 2, Impaired Glucose Tolerance, Impaired Fasting Glucose
- Trial name
- NCT01933529
- Testing
- ARA 290
- Where
- Sweden
- Volunteers
- 24 people
- Sponsor
- Claes-Göran Östenson
T2DM, Type 2 Diabetes Mellitus
A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DM
The aim of the study is to compare the efficacy and safety of two XW003 doses versus dulaglutide as add-on therapy to metformin in participants with type 2 diabetes mellitus (T2DM)
- Trial name
- NCT05680129
- Testing
- Ecnoglutide high dosage, Ecnoglutide low dosage, Dulaglutide
- Where
- China
- Volunteers
- 623 people
- Sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.
Painful Diabetic Neuropathy
Low-Dose Naltrexone for the Treatment of Painful Diabetic Neuropathy
Diabetes affects more than 30 million people in the United States and is a leading cause of morbidity. Over 25% diabetics also suffer from debilitating painful diabetic neuropathy in the lower legs and feet.
- Trial name
- NCT04678895
- Testing
- Naltrexone
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Diabetes type2, Obesity
The RESET System Pivotal Clinical Trial (Protocol Revision K)
A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Evaluating the RESET System for Glycemic Improvement in Patients with Inadequately Controlled Type 2 Diabetes and Obesity, the STEP-1 Study.
- Trial name
- STEP-1 (NCT04101669)
- Testing
- RESET Liner
- Where
- 27 sites in United States
- Volunteers
- 264 people
- Sponsor
- Morphic Medical Inc.
Diabetic Nephropathy
Effect of Topiroxostat on Urinary Albumin Excretion Early Stage Diabetic Nephropathy and Hyperuricemia With or Without Gout
The purpose of this study is to investigate the effect of topiroxostat on urinary albumin excretion and the safety in patients with early stage diabetic nephropathy and hyperuricemia with or without gout.
- Trial name
- UPWARD (NCT02327754)
- Testing
- Topiroxostat BID, (Oral daily dosing for 28 weeks)
- Where
- Japan
- Volunteers
- 60 people
- Sponsor
- Sanwa Kagaku Kenkyusho Co., Ltd.
Diabetes Mellitus, Type 2
Assessment of Insulin Glargine in Type 2 Patients for Good Glycemic Control
Primary objective: To observe the efficacy of the forced titration to reach good glycemic control in Lantus treated patients Secondary objectives: To assess the forced titration on physician and patient satisfaction To evaluate…
- Trial name
- LANTIT (NCT00701831)
- Testing
- Insulin glargine
- Where
- Turkey (Türkiye)
- Volunteers
- 241 people
- Sponsor
- Sanofi
Hypertension, Diabetes
A Clinical Study to Evaluate Safety & Efficacy of the Combination of Aliskiren, Valsartan & Hydrochlorothiazide in Diabetic Hypertensive Nonresponder Patients
To evaluate the blood pressure lowering effect and safety of aliskiren used in combination with valsartan/hydrochlorothiazide in diabetic patients with essential hypertension, not adequately responsive to the combination of…
- Trial name
- NCT00219102
- Testing
- aliskiren
- Where
- 7 sites in United States, Belgium and 5 more
- Volunteers
- 336 people
- Sponsor
- Novartis
Diabetes Mellitus
Evaluation of Diabetic Foot Wound Healing Using Hydrogel/Nano Silver-based Dressing vs. Traditional Dressing
Background: The wound dressings perform a crucial role in the cutaneous wounds' management due to their ability to protect wounds and promote dermal and epidermal tissue regeneration.
- Trial name
- NCT04834245
- Testing
- Hydrogel/nano silver-based dressing
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Magda Bayoumi
Diabetes Mellitus, Type 2
GLP-1 Receptor Agonist Lixisenatide Versus Exenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin
The purpose of this study is to compare the benefits and risks of lixisenatide (AVE0010) in comparison to exenatide (Byetta®), as an add-on treatment to metformin, over a period of 24 weeks of treatment, followed by an extension.
- Trial name
- GETGOAL-X (NCT00707031)
- Testing
- Lixisenatide (AVE0010), Pen auto-injector, Exenatide
- Where
- 18 sites in United States, Argentina and 16 more
- Volunteers
- 639 people
- Sponsor
- Sanofi
Diabetes
HEdia eXercise Algorithm - HEXA Study.
A randomised controlled crossover pilot study to evaluate safety and efficacy of a digital insulin bolus calculator with a physical activity module
- Trial name
- NCT05458167
- Testing
- Hedia Diabetes Assistant bolus calculator with a physical activity module
- Where
- Denmark
- Volunteers
- 20 people
- Sponsor
- Hedia ApS
Type 2 Diabetes
A Guided Self-determination Intervention Versus Attention Control for People With Type 2 Diabetes in Outpatient Clinics
Background In management of type 2 diabetes, autonomy supporting interventions may be a prerequisite to achieve 'real life' patient engagement and more long-term improvement.
- Trial name
- OVERCOME (NCT04601311)
- Testing
- Guided self-determination, Personal support in goal-pursuing
- Where
- Denmark
- Volunteers
- 224 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Diabetes Mellitus, Type 2
A Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602 in Type 2 Diabetic Patients
The purpose of this study is to assess the safety and tolerability of MSDC-0602 and to evaluate the reduction in fasting plasma glucose in patients with Type 2 diabetes.
- Trial name
- NCT01280695
- Testing
- MSDC-0602 100 mg, MSDC-0602 250 mg, Pioglitazone
- Where
- 14 sites in United States
- Volunteers
- 129 people
- Sponsor
- Metabolic Solutions Development Company
Type 2 Diabetes
Training, Detraining, Retraining and Glycemic Control in Patients With Type 2 Diabetes
This study examine the effects of training, detraining and retraining, using a combined strength and aerobic exercise program, on physiological parameters in patients with type 2 diabetes.
- Trial name
- NCT01580475
- Testing
- Training - detraining - retraining
- Where
- Greece
- Volunteers
- 13 people
- Sponsor
- Democritus University of Thrace
Diabetes, Diabetes Mellitus, Type 2
A Randomised Controlled Clinical Trial in Type 2 Diabetes Comparing Semaglutide to Placebo and Liraglutide
This trial was conducted in Europe,Asia and Africa. Study participants were randomised evenly to treatment with semaglutide (0.1 mg QW - 1.6 mg QW, 6 treatment arms, placebo or liraglutide (1.2 mg QD, or 1.8 mg QD).Treatment…
- Trial name
- NCT00696657
- Testing
- semaglutide, liraglutide
- Where
- 77 sites in Austria, Bulgaria and 12 more
- Volunteers
- 415 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
Lifestyle Interventions for Long Term Diabetes Control
Lifestyle interventions have been shown to reduce heart disease risk and improve blood sugar control in clinical trials. This project will investigate whether those lifestyle interventions can be implemented long-term, in usual…
- Trial name
- NCT00364312
- Testing
- diet and physical activity
- Where
- United States
- Volunteers
- 390 people, healthy volunteers welcome
- Sponsor
- University of Virginia
Type 2 Diabetes Mellitus(T2DM)
Effectiveness of Text Messaging Intervention to Improve Dietary Behaviors Among Patients with Type 2 Diabetes Mellitus in Low Resource Area of Sabah (DTEXT-SBH)
The goal of this clinical trial is to learn if sending three (3) text messages per week over a six (6) months period to people with Type 2 Diabetes in areas with lack access to dietitian could help them stick to a healthier diet.
- Trial name
- DTEXT-SBH (NCT06587581)
- Testing
- Control Group, Intervention Group
- Where
- Malaysia
- Volunteers
- 62 people
- Sponsor
- Universiti Malaysia Sabah
Diabetes Mellitus, Coronary Artery Bypass
Remote Ischemic Preconditioning in Type 2 Diabetic Patients Undergoing CABG
This randomized, double-blind, prospective clinical trial aims to investigate the effect of remote ischemic preconditioning (RIPC) on myocardial protection in patients with type 2 diabetes mellitus undergoing elective coronary…
- Conditions
- Diabetes Mellitus, Coronary Artery Bypass, Remote Ischaemic Conditioning
- Trial name
- NCT06977230
- Testing
- Remote Ischemic Preconditioning
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- Muğla Sıtkı Koçman University
Obesity, Overweight
A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes
The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to investigate the safety and efficacy of LY3841136 for chronic weight management alone or in combination with Tirzepatide across a…
- Trial name
- NCT06603571
- Testing
- LY3841136, Tirzepatide
- Where
- 52 sites in United States, Argentina
- Volunteers
- 367 people
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.